Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
GSK and Sanofi signed up for Gates Foundation vaccine R&D initiative
Nov. 1, 2013
 
Vaccine manufacturers are often criticized for investing in shots aimed at high-margin Western markets, while neglecting diseases affecting the developing world. This week, the Bill & Melinda Gates Foundation set up a project to spur development in neglected areas by cutting the financial risk of early research.
GlaxoSmithKline and Sanofi are the first companies to join Bill & Melinda Gates Foundation's project, called the Vaccine Discovery Partnership (VxDP) to develop vaccines from preclinical through to Phase IIa in less developed areas. By for the projects, the Gates Foundation will provide financial support to early-phase vaccine research. Once at proof-of-concept stage, other funding mechanisms will come on board.
 
Merck's next-gen HPV vaccine showed good results in phase III trial
Nov.3,2013
 
Merck's new HPV vaccine V503, which was designed to guard against 9 strains of HPV showed good results in phase III trial, comparable with Gardasil in 4 strains that Gardasil can protect against, and far superior than Gardasil in combating the other 5 strains.
 
One dose of GSK HPV vaccine gives durable immune response
Nov.6,2013
 
A randomized trial of GlaxoSmithKline's bivalent HPV vaccine Cervarix in Costa Rica found that one dose of the vaccine can also provide protection and the antibody level can be stable for 4 years, suggesting that one dose might do some good. The result is a positive for the developing world where the three-dose shots might be inconvenient and costly.
 
5th Global Biopharma Annual Conference held in Nanjing
Nov. 8, 2013
 
This year-end grand summit for biopharmaceutical industry included three different streams, i.e. 5th China Vaccine Industry Summit, 1st Plasma Products Industry Summit, and 2nd Recombinant Protein Drugs Industry Summit. Dr. Ke Wu moderated the panel discussion of Grand Conference on the topic of "Opportunities and Challenges for China Biologicals Industry". He also chaired the vaccine summit of first day.
 
BravoVax welcomed the expert of WHO
Nov. 10, 2013
 
The member of BravoBio, BravoVax, welcomed the expert of WHO last weekend. The distinguished guest had more than 20 years' profound experiences on vaccine R&D, manufacture and regulatory in multiple countries. The two-day discussion and training to the BravoVax team is fruitful.
 
Novartis to sell off vaccine and other non-competing units
Nov.14,2013
 
Due to the unsatisfactory performance of blood-transfusion diagnostics unit compared to others, Novartis agreed to sell its blood-transfusion diagnostics unit to Spain-based Grifols for $1.68 billion. Novartis may sell of some other units like vaccines, animal health and consumer products.
 
Novavax reported positive Phase I data for H7N9 vaccine
Nov.19,2013
 
Due to the unsatisfactory performance of blood-transfusion diagnostics unit compared to others, Novartis agreed to sell its blood-transfusion diagnostics unit to Spain-based Grifols for $1.68 billion. Novartis may sell of some other units like vaccines, animal health and consumer products.
 
Roche's Kadcyla got EU approval for treating breast cancer
Nov.21,2013
 
Roche's kadcyla, referred to as a "super Herceptin," has got the approval to treat patients with previously treated HER2-positive advanced breast cancer from the European Commission this Wednesday, following its approval from FDA in February. Patients taking Kadcyla survived almost 6 months longer than on the standard treatment of lapatinib and Xeloda. Kadcyla is reportedly priced in the U.S. at $9,800, twice the cost of Herceptin, and is forecasted to achieve $2.5 billion sales within 5 years.
 
GAVI adds inactivated polio vaccine to routine immunization program
Nov.28,2013
 
GAVI is adding the inactivated poliovirus vaccine (IPV) to the list of routine immunization in the world's 73 poorest countries. GAVI is also encouraging countries to co-finance IPV into routine immunization program. Sanofi welcomed the decision.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next